SMN1 and proximal spinal muscular atrophy: Collectively, these findings suggest that pharmacological inhibition of JNK may serve as a therapeutic strategy to prevent neurodegeneration, either in combination with SMN-enhancing approaches for treating severe forms of SMA, or as a stand-alone, SMN-independent intervention for moderate and mild SMA cases.